Tore von Würden – Country Director Denmark & Iceland,…
Tore von Würden talks through Amgen Denmark’s focus areas of osteoporosis, cardiovascular disease, haematology, and oncology, where it hopes not…
Tagged with M&A
Is Everything So Wrong at GSK?
British pharmaceuticals giant, GSK, one of the UK’s largest companies by market capitalization, is once again finding itself under the spotlight as…
Thomas Kerscher – Head of Europe, Aspen
Aspen’s European Head Thomas Kerscher explains how the sale of the company’s thrombosis portfolio to Mylan has led to an organisational…
Brazil Pharma News: EMS Sales Soar; Irregularities in Indian…
The latest news from Brazilian pharma, including an investigation into the country’s deal with Indian lab Bharat Biotech to purchase COVID-19…
Tillotts CEO Talks SME M&A Principles
Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a specialty pharma player focused on the digestive system, has overseen a number…
Takeda Pivoting to Growth Amid Renewed Focus on “Core Assets”
“This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey,” said…
Politics and Pharma M&A in Argentina
The COVID-19 pandemic has caused economic and social disruption and affected the behaviour of both consumers and producers in Argentina, with an…
Haijun Dong – CEO, BioDuro-Sundia
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of the largest Contract Research,…
Thomas A. Tóth von Kiskér – CEO & Board Member,…
Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a Switzerland-based specialty pharma player focused on the digestive system,…
Viatris: Cost-Cutting Needed at New Generics Behemoth
In November 2020, after months of delay caused by COVID-19 disruptions and a US antitrust roadblock, Mylan and Pfizer's Upjohn generics unit finally…
J&J’s Momenta Deal A Further Sign of Big Pharma’s Rare…
In the wake of Sanofi’s USD 3.7 billion tie-up for US biotech Principia, J&J has moved to bolster its autoimmune portfolio with the acquisition…
Sanofi Buys Principia for USD 3.7 Billion as Part of Specialty…
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full…
